Form 4: CorMedix Director Exercises Options, Sells Shares
Insider Transaction Report
CorMedix Director Janet Dillione exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged trading plan.
Summary
- Janet Dillione, a Director at CorMedix Inc. (CRMD), reported changes in her beneficial ownership of common stock.
- On December 9, 2025, Dillione exercised options to acquire 19,000 shares of common stock at an exercise price of $9.55 per share.
- On the same date, she also exercised options to acquire an additional 15,000 shares of common stock at an exercise price of $5.63 per share.
- Immediately following these exercises, Dillione disposed of 34,000 shares of common stock at a weighted average price of $12.00 per share, with trades ranging from $12.00 to $12.02.
- These transactions were executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
- After these transactions, Dillione's direct beneficial ownership of CorMedix common stock stands at 48,473 shares.
- The options exercised were fully vested, with the 19,000 options granted on February 21, 2016, and the 15,000 options granted on February 25, 2020.
Sentiment
Score: 5
Explanation: The sentiment is neutral. This is a routine insider transaction involving the exercise of options and a subsequent sale of an equivalent number of shares, executed under a pre-arranged 10b5-1 plan. It does not inherently signal strong positive or negative sentiment about the company's future prospects.
Positives
- The exercise of options indicates that the stock price was above the exercise price, allowing the director to realize a gain.
- The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planning and reducing concerns about opportunistic insider trading.
Negatives
- A director selling shares, even under a pre-arranged plan, can sometimes be perceived as a lack of confidence, though the amount sold was equal to the amount exercised.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction report and does not provide specific industry context. Insider transactions are common across all industries, and the use of a Rule 10b5-1 plan is a standard practice for corporate insiders to manage their stock holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 12/09/2025 | This indicates a pre-arranged trading plan, which is a common corporate governance practice to allow insiders to trade company stock without being accused of trading on material non-public information. |
Stakeholder Impact
- Shareholders: The sale of shares by a director could be viewed neutrally given it was a cashless exercise or sell-to-cover transaction under a 10b5-1 plan, rather than a discretionary sale of existing holdings. The overall impact on shareholder sentiment is likely minimal.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 02/21/2016 | Grant date for 19,000 stock options. |
| 02/25/2020 | Grant date for 15,000 stock options. |
| 12/09/2025 | Date of stock option exercises and subsequent sale of common stock. |
| 12/11/2025 | Signature date of the reporting person for the Form 4 filing. |
| 02/21/2026 | Expiration date for 19,000 stock options. |
| 02/25/2030 | Expiration date for 15,000 stock options. |
Keywords
CorMedix, CRMD, Form 4, Insider Transaction, Stock Options, Director, Share Sale, Beneficial Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.